FUNDING OPPORTUNITIES

 FUNDING OPPORTUNITIES

 

  • National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)

With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.  

Link: https://grants.nih.gov/grants/guide/pa-files/PAR-20-077.html

Application date line: The first standard due date for this FOA is May 25, 2020  

All applicants are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply corrections to errors found in the application during the submission process by the due date..

 

  • National Alzheimer’s Coordinating Center 

This FOA invites applications for a National Alzheimer’s Coordinating Center (NACC) whose purpose is to serve NIA and the Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD) field as 1) a national data resource, collecting data from the Alzheimer’s Disease Research Centers (ADRCs), affiliated data, and sample repositories; 2) a facilitator of current and future AD/ADRD research; and 3) the central hub for organizing and enabling communication within and outside the ADRC program, including annual meetings and steering committees.

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-014.html

Application Date Line: June 17, 2020

No late applications will be accepted for this Funding Opportunity Announcement. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

 

  • Childhood Asthma in Urban Settings -Clinical Research Centers

 

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the NIAID Childhood Asthma in Urban Settings Clinical Research Network Clinical Research Centers (CAUSE-CRCs). The CAUSE-CRCs will conduct both network-wide and site-specific clinical studies and trials with the ultimate goal of developing effective asthma treatment or prevention approaches applicable to children residing in low-income urban settings. For network-wide clinical research projects and other network functions, the CAUSE-CRCs will work closely with the CAUSE Leadership Center (CAUSE-LC).

 

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-19-073.html

Application Date Line: June 19, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date

  • Childhood Asthma in Urban Settings Clinical Research Network- Leadership Center (UM1 Clinical Trial Required)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the NIAID Childhood Asthma in Urban Settings Clinical Research Network Leadership Center (CAUSE-LC). The CAUSE-LC will provide the overall scientific strategy and organizational structure to the CAUSE Clinical Research Network and will interact closely with the CAUSE Clinical Research Centers (CAUSE -CRCs) to support the conduct of multi-site clinical studies and trials with the ultimate goal of developing effective interventions or asthma prevention approaches applicable to children residing in low-income urban settings.

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-19-074.html

Application Date Line: June 19, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Mechanisms of Disparities in Chronic Liver Diseases and Cancer

The purpose of the initiative is to support multidisciplinary exploratory or developmental research to understand the underlying etiologic factors and mechanisms that contribute to population-level disparities in chronic liver diseases and liver cancer in the U.S.

Link: https://grants.nih.gov/grants/guide/pa-files/PAR-20-081.html

Application date line: April 1, 2020, April 1, 2021, and April 1, 2022

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date

Department of Health and Human Services

This funding opportunity announcement is designed to support biomedical data repositories. Biomedical data repositories under this announcement should have the primary function to ingest, archive, preserve, manage, distribute, and make accessible the data related to a particular system or systems. Support for data curation must be limited to that which improves the efficiency and accessibility of data ingestion, management, and use and reuse by the user communities. Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the repository. Applications that have a significant focus on software and tool development are not appropriate for this activity.

Link: https://grants.nih.gov/grants/guide/pa-files/PAR-20-089.html

Application Date Line: January 25, 2021; September 24, 2021; January 25, 2022; September 26, 2022; January 25, 2023

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Biomedical Knowledge base

 This funding opportunity announcement is designed to support biomedical knowledgebases. Biomedical knowledgebases under this announcement should have the primary function to extract, accumulate, organize, annotate, and link growing bodies of information related to core datasets. Support for data curation should include efficient and effective methods of curation that scale to the needs of the community and include semi-automated methods. Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the knowledgebase.

Applications that have a significant focus on software or tool development are not appropriate for this activity.

 

Link: https://grants.nih.gov/grants/guide/pa-files/PAR-20-097.html

Application Date Line: September 25, 2020; January 25, 2021; September 24, 2021; January 25, 2022; September 26, 2022; January 25, 2023

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Combating Antibiotic-Resistant Bacteria (CARB) Interdisciplinary Research Units

This Funding Opportunity Announcement (FOA) solicits applications to establish Combating Antibiotic-Resistant Bacteria (CARB) Interdisciplinary Research Units (CARBIRUs) focused on improving our understanding of bacterial and host factors important for antibacterial resistance and infection to inform development of new approaches to prevent, diagnose, and treat antibacterial-resistant infections. 

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-001.html

Application Date Line: May 8, 2020 

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply corrections to errors found in the application during the submission process by the due date.

 

Research Answers to National Cancer Institute’s (NCI) Provocative Questions

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions Initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI’s priorities in cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

 

Some of these “Provocative Questions” (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances.

 

The current issuance of the PQ Initiative includes an updated set of 9 PQs. Each research project proposed in response to this FOA must be focused on addressing the research problems defined by a specific PQ selected from the list. Projects proposed to address PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged if they serve the scientific focus of the selected PQ.

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-004.html

Application Date Line: November 17, 2020

No late applications will be accepted for this Funding Opportunity Announcement.

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

 

Mendelian Genomics Data Coordinating Center

The purpose of this FOA is to solicit applications to develop and implement a Mendelian Genomics Data Coordination Center (MGDCC) for the Mendelian Genomics Research Consortium. The MGDCC will be responsible for managing the release of data and findings generated under the program, as well as program outreach, ensuring maximum utility for the research community. The MGDCC will also coordinate program logistics, supporting effective working groups and meetings. Finally, the MGDCC will oversee the program’s Opportunity Fund, providing rapid turnaround short-term funding for functional follow-up studies to program findings.

 

 Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-008.html

Application Date Line:

April 15, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). No late applications will be accepted for this Funding Opportunity Announcement.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

 

Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)

Human cell-based assays (e.g., using induced pluripotent stem cells) hold promise for identifying molecular, cellular and circuit defects, identifying novel targets and developing new therapeutics for patients with complex brain and other nervous system disorders. However, the methods to generate and analyze relevant cells and circuits must be made robust, replicable and predictive for normal nervous system function as well as pathophysiology. Cells grown in monolayer culture remain a mainstay for many assays, including high-throughput screening, but a drawback of these reductionist assays is that they cannot resolve many developmental and aging trajectories, anatomical features and circuit activity representative of in vivo nervous system function.

Link: https://grants.nih.gov/grants/guide/pa-files/PAR-20-055.html

Application date line: The first standard due date for this FOA is February 5, 2020.

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date

 

Treating Diabetes Distress to Improve Glycemic Outcomes in Type 1 Diabetes (R01 Clinical Trial Required)

 

Management of type 1 diabetes (T1D) requires a complex regimen of blood glucose monitoring, medication dosing, and adjustments in diet and physical activity to achieve tight glucose control while avoiding hypoglycemia. These constant self-management demands, as well as fear of complications, are associated with diabetes distress, a negative emotional response to the chronic burden of living with T1D. Diabetes distress is very common in individuals with T1D and is distinct from psychological disorders such as depression. Diabetes distress may significantly impact medication taking and other self-care behaviors and has been linked to higher HbA1c. Parents of children with type 1 diabetes, as well as partners of individuals with type 1 diabetes, may also experience diabetes distress, sometimes stemming from perceptions of guilt, which may adversely impact their ability to provide management support for their child or partner.

There is growing awareness of the importance of patient-reported outcomes (PROs), including diabetes distress, in the management of T1D. PROs complement biomedical outcomes by capturing patient experiences with disease management beyond that measured by a biomedical assay, such as HbA1c. Recently, clinical care guidelines have emphasized the importance of assessing and addressing psychosocial care as a critical and integral part of the treatment of individuals with diabetes. Such guidelines include the recommendation that individuals with diabetes should be monitored for diabetes distress at medical appointments and be referred for enhanced diabetes education or behavioral counseling, especially when self-care is suboptimal. The most efficacious and cost-effective approaches for ameliorating diabetes distress have not been determined.

 

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-021.html

Application Date Line: March 26, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

 

Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortium on Beta Cell Death and Survival (CBDS)] (U01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) requests applications to explore human pancreatic tissues for the discovery of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the discovery of early biomarkers of T1D pathogenesis, the development of diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification and biological validation of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), whose mission is to better define and detect the mechanisms of beta cell stress and destruction central to the development of T1D in humans, with­ the long-term goal of protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and of preventing the progression to autoimmunity. The CBDS is part of a collaborative research framework, the Human Islet Research Network (HIRN, https://hirnetwork.org/), whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This FOA will only support studies with a primary focus on increasing our understanding of human disease biology (as opposed to rodent or other animal models). This FOA will not accept applications proposing a clinical trial.

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-024.html

Application Date Line: April 1, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed)

The New Investigator Gateway Award in T1D Research is designed to ensure that a robust pipeline of talented new investigators will continue to embark on successful careers in T1D research. In addition to providing support for preliminary research, the Gateway program provides an opportunity for new Program Directors/Principal Investigators (PD/PIs) to pursue their studies within the intellectual environment of a select number of large, ongoing collaborative research programs. Embedding awardees within an established scientific framework in each of these consortia will provide unique opportunities for New and Early Stage Investigators to increase their understanding of key questions in the field, to network, and to establish unique and potentially long-lasting collaborations that will propel their careers forward. It is anticipated that the Gateway award will provide the support needed to enhance the success of future R01 submissions from New Investigators interested in pursuing careers in T1D research.

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-026.html

Application Date Line: March 25, 2020 and November 3, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research addressing barriers that limit progress toward effective open- and closed-loop glucose control systems. Proposed research should tackle important obstacles at the level of sensing, hormone formulation and delivery, self-management decision support systems, and/or design of automated controllers/algorithms able to manage an integrated platform. This research may contribute to development of affordable and user friendly technologies to improve glucose control in patients with type 1 diabetes.

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-029.html

Application Date Line: April 7, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

BRAIN Initiative: Biology and Biophysics of Neural Stimulation and Recording Technologies (R01 Clinical Trials Optional)

A central goal of the BRAIN Initiative is to develop new and improved technologies suitable for recording from as well as controlling specified cell types and circuits to modulate and understand function in the central nervous system. In order to accomplish these goals, further information is needed to understand the function of current technologies used for recording or stimulating the nervous system.

This RFA accepts grant applications in two related but distinct areas. The first is to systematically characterize, model, and validate the membrane, cellular, circuit, and adaptive-biological responses of neuronal and non-neuronal cells to various types of stimulation technologies. The second is to understand the biological and bioinformatic content of signals recorded from neuronal and non-neuronal cells and circuits. Development of new technologies, therapies and disease models is outside the scope of this FOA. Activities related to enabling the simultaneous use of multiple recording or stimulation technologies are allowed.

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-20-006.html

Application Date Line: March 24, 2020, June 2, 2020, October 1, 2020, February 2, 2021, June 1, 2021, October 1, 2021, February 1, 2022, June 1, 2022, and October 3, 2022

by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

White Matter Lesion Etiology of Dementia in the U.S. Including in Health Disparity Populations (U19 – Clinical Trial Not Allowed)

Despite established associations between white matter lesions and cognitive impairment including dementia, little prospective information is available to define the characteristics of white matter lesions and associated comorbid clinical factors that cause further cognitive impairment, ultimately resulting in dementia.  This initiative will support one large prospective clinical research study in the U.S. of patients engaged with the health care system because of incidental white matter lesions found on neuroimaging, who present with cognitive complaints, and who thus are at risk for cognitive decline. The goal will be to determine the volume and anatomical features that are both necessary and sufficient to cause cognitive impairment or dementia. The study will include health disparity populations and will examine additional clinical factors and comorbidities, including those along the AD/ADRD spectrum, that may be effect modifiers of the relationship between white matter lesions and cognitive impairment, including dementia. Clinical trial-ready biomarkers of vascular contributions to cognitive impairment and dementia (VCID) should be utilized, further developed, and/or subject to implementation research in this study. Secondary goals include: identifying clinical and mechanistic targets for future VCID interventional trials; determining interrelationships (cross-sectional and longitudinal) among white matter lesions, cerebro- and cardio-vascular disease, and risk factors including dementia-relevant genes. Applicants are encouraged, when scientifically advantageous, to utilize existing resources for VCID research, e.g. MarkVCID, Alzheimer’s Centers, and large NIH-funded prospective cohort studies (e.g. Framingham, ARIC, CHS, NOMAS, etc.) as well as other dementia resources. Given the diverse and complex challenges involved in the design and execution of this study, the award will provide for up to one-year initial protocol refinement and study start-up phase, to be followed by an implementation phase, for a total award period of up to 6 years.

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-20-013.html

Application Date Line: March 31, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.